NCT04914663NARecruiting
All-extremity Exercise During Breast Cancer Chemotherapy
University of Florida
Start Date
4/5/2024
Completion Date
1/31/2027
Summary
Currently, there are 3.5 million breast cancer survivors in the United States and this number is expected to increase dramatically. The proposed research will examine whether a novel exercise intervention for breast cancer patients who are undergoing chemotherapy protects against cardiovascular dysfunction. Findings may have implications for cardiovascular disease prevention in this population.
Eligibility Criteria
Age Range: 18 years to 85 years
Inclusion Criteria:
* Active diagnosis of primary invasive non-metastatic breast cancer, stages I-III
* Female
* 18 to 85 years of age
* Scheduled to initiate neoadjuvant or adjuvant chemotherapy (anthracycline, alkylating agent and/or taxane)
* Absence of contraindications to exercise
* Study clinician approval
* Able to give consent
* Informed consent obtained from the subject and documentation of subject agreement to comply with study-related process
Exclusion Criteria:
* Do not meet inclusion criteria
* Receiving targeted therapies (CDK4/6 or PARP inhibitors)
* Receiving radiation therapy concurrent with chemotherapy
* Lymphedema stage ≥ 2 prior to study enrollment
* Any relevant cardiovascular diseases (stroke, heart failure, myocardial ischemia during maximal graded exercise test, myocardial infarction, angina pectoris, coronary artery bypass surgery or angioplasty or coronary stent)
* Current participation in other experimental interventions that may confound interpretation of study findings (e.g., dietary intervention for weight loss)
Interventions
BEHAVIORAL
Exercise training
Conditions
Breast Cancer
Locations
Integrative Cardiovasculal Physiology Laboratory, University of Florida
Gainesville, Florida 32611
United States